SynthesisScientific reports2025
The prediction value of LOXL-2 in the clinical pathology and prognosis of cancers: A meta-analysis and bioinformatics analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysyl oxidase-like 2 (LOXL2) is a key enzyme involved in extracellular matrix remodeling, and its high expression is associated with cancer progression. This study aims to assess the relationship between LOXL2 expression and clinical prognosis in cancer patients through meta-analysis and bioinformatics. A comprehensive literature search was conducted in PubMed, Cochrane Library, Web of Science, and Embase databases until December 2023. Studies reporting the relationship between LOXL2 expression and overall survival (OS) or disease-free survival (DFS) were included. Hazard ratios (HR) and odds ratios (OR) with 95% confidence intervals (CIs) were calculated. Subgroup analyses and meta-regression were performed to evaluate sources of heterogeneity. A total of 30 studies with 5021 patients were included. High LOXL2 expression was significantly associated with poor OS (HR = 1.92, 95% CI: 1.65-2.23, P < 0.001) and DFS (HR = 1.81, 95% CI: 1.39-2.36, P < 0.001). LOXL2 expression correlated with several clinicopathological features, including tumor size (OR = 1.53, P = 0.006), lymph node metastasis (OR = 1.71, P = 0.016), and distant metastasis (OR = 2.63, P < 0.001). Sensitivity analysis confirmed the robustness of these results. High LOXL2 expression is a reliable prognostic biomarker for various cancers, correlating with poor survival outcomes and advanced clinical features. LOXL2 may serve as a therapeutic target to improve cancer prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.